Guided Therapeutics

Guided Therapeutics FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Guided Therapeutics (GTHP) as of Oct 18, 2026 is 33.48 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 46.30 % — a change of -27.69% (lower).

FCF Conversion

33.48 %

YoY

-27.69%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Guided Therapeutics is 2025 33.48 % . FCF Conversion Rate (FCF/EBITDA) of Guided Therapeutics was 2024 46.30 % . It decreases by -27.69% lower compared to the previous year.

The Guided Therapeutics FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
-134.45 USD
Jan 1, 2019
42.01 USD
Jan 1, 2020
672.40 USD
Jan 1, 2021
77.58 USD
Jan 1, 2022
34.78 USD
Jan 1, 2023
50.04 USD
Jan 1, 2024
46.30 USD
Jan 1, 2025
33.48 USD
The Guided Therapeutics FCF Conversion history
YEARFCF ConversionYoY
33.48 %-27.69%
46.30 %-7.49%
50.04 %+43.87%
34.78 %-55.17%
77.58 %-88.46%
672.40 %+1,500.60%
42.01 %-131.25%
-134.45 %-1,355.95%
10.70 %-70.26%
36.00 %-15.56%
42.63 %-33.43%
64.04 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Guided Therapeutics Stock analysis

What does Guided Therapeutics do? Guided Therapeutics Inc, with ticker GTHP and ISIN US40171F5017, is a health care company headquartered in Norcross, Georgia. The company has 6 employees and went public on July 1, 1997. Guided Therapeutics focuses on developing medical devices, particularly utilizing biophotonic technology for cancer detection. The company's primary product is the LuViva Advanced Cervical Scan, a non-invasive device designed to detect cervical cancer and precancers. The LuViva device scans the cervix with light and analyzes the reflected and fluorescent light to provide results at the point of care. It serves as an alternative to conventional cervical cancer screening methods, targeting two main applications: as a screening tool and as a triage method for traditional screening processes. The company develops prototypes and conducts limited clinical studies using its biophotonic technology, which is central to its approach for detecting esophageal cancer. Guided Therapeutics operates within the health care sector and industry, with its website at https://www.guidedinc.com/. The company's current operational focus is on the development and marketing of the LuViva device, though it has also explored applications in esophageal cancer detection through biophotonic technology. Guided Therapeutics has a small workforce of six full-time employees, reflecting its current scale of operations. Guided Therapeutics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Guided Therapeutics stock

FCF Conversion Rate (FCF/EBITDA) of Guided Therapeutics is 33.48 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Guided Therapeutics changed from 46.30 % to 33.48 %, representing a -27.69% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Guided Therapeutics since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Guided Therapeutics with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Guided Therapeutics

All Key Metrics — Guided Therapeutics